Key result
Flecainide therapy effectively controlled fetal supraventricular tachycardia in a twin pregnancy after beta-sympathomimetic drug-induced arrhythmia.
Why the study?
Does flecainide therapy control fetal supraventricular tachycardia in a twin pregnancy?
Case Report (n=1)
Does flecainide therapy control fetal supraventricular tachycardia in a twin pregnancy?
Flecainide is an effective therapy for managing fetal supraventricular tachycardia in a twin pregnancy.
May inform fetal SVT management in twins; leaves open need for prospective data before practice change.
BACKGROUND: Magnetocardiography and M-mode fetal echocardiography are non-invasive techniques capable of identifying fetal arrhythmias. The STAN-fetal scalp electrode system can record the fetal echocardiogram in labor. CASE: A patient was admitted to hospital with preterm contractions and cervical insufficiency at 28 weeks of gestation. After treatment with a beta-sympathomimetic drug (Partusisten) one fetus developed supraventricular tachycardia. After terminating the Partusisten medication, there was no effect on the fetal arrhythmia and flecainide therapy was initiated. Maintenance dosages controlled the condition thereafter. Cardiac time intervals of a fetus in labor can be presented, which did not change significantly throughout the first stage of labor. CONCLUSION: Flecainide is an effective therapy for supraventricular tachycardias in a twin pregnancy. Analyzing the cardiac time intervals during pregnancy can improve perinatal outcome.
No takes yet. Share an insight, caveat, or question.
Schiermeier et al. (2008) conducted a case report in Fetal supraventricular tachycardia in a twin pregnancy (n=1). Flecainide was evaluated on Control of fetal supraventricular tachycardia. Flecainide therapy effectively controlled fetal supraventricular tachycardia in a twin pregnancy after beta-sympathomimetic drug-induced arrhythmia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: